Abaloparatide: First Global Approval
Sign Up to like & getrecommendations! Published in 2017 at "Drugs"
DOI: 10.1007/s40265-017-0780-7
Abstract: Abaloparatide (Tymlos™) is a synthetic peptide analogue of human parathyroid hormone-related protein that was developed by Radius Health as an osteoanabolic agent for the treatment of postmenopausal osteoporosis. Abaloparatide acts through selective activation of the… read more here.
Keywords: abaloparatide first; global approval; treatment postmenopausal; first global ... See more keywords